Inhibikase Therapeutics sells 25,000,000 shares via ATM for gross proceeds of $50 million
IKT•Use of proceeds and runway
Proceeds, combined with existing cash, are expected to fund operations through the Part B topline readout of the Phase 3 IMPROVE-PAH study.
The runway assumption depends on full exercise of the outstanding Series A and B warrants.
ATM share sale and proceeds
Inhibikase Therapeutics sold 25,000,000 common shares to RA Capital Management via its at-the-market facility for gross proceeds of $50 million.
